Pylum Biosciences, Inc.

SOUTH SAN FRANCISCO, CA · Founded 2016 · Biotech · Private

Avidocin platform technology that generates bactericidal protein complexes targeting specific bacterial pathogens

Claim this profile

Follows are private to you and power your alerts

Updated · pylumbio.com

Sector
Biotech
Headquarters
SOUTH SAN FRANCISCO, CA
Founded
2016
Latest Form D
$990K, Mar 2020
Total capital
$990K
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$990K
1 Form D · last Mar 2020
80 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
1 pending · first 2024
Rank in peer group#481 of 1449

Capital timeline

2020FEDERAL ↑EQUITY ↓Cumulative $990K1st Form D$990K
2020FEDERAL ↑EQUITY ↓Cumulative $990K1st Form D$990K

Latest events

  • Private capital raisedForm D · SEC · 1st filing$990K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#481 · top 33%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • David MartinDirectorNamed in SEC Form D filings
  • James KnightonExecutive Officer, DirectorNamed in SEC Form D filings
  • Jeffrey MillerDirectorNamed in SEC Form D filings
  • Kevin CameronDirectorNamed in SEC Form D filings
  • Miguel BarbosaDirectorNamed in SEC Form D filings
  • Stephen CreagerExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 2

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .